MINI FUTURE SHORT - GALAPAGOS | Real-time Euronext Paris 03:28:11 16/05/2024 pm IST | ||
| 1.655 EUR | -4.61% |
|
| Current month | -2.25% | ||
| 1 month | +7.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GALAPAGOS NV
Latest news about GALAPAGOS NV
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 1.655 | -4.61% |
| 15/24/15 | 1.735 | -3.34% |
| 14/24/14 | 1.795 | +1.13% |
| 13/24/13 | 1.775 | 0.00% |
| 10/24/10 | 1.775 | +1.72% |
Real-time Euronext Paris
Last update May 16, 2024 at 03:28 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GALAPAGOS NV |
| Issuer | 
BNP Paribas
|
| VQ8LB | |
| ISIN | NLBNPNL2GN21 |
| Date issued | 10/08/2023 |
| Strike | 44.14 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.795 € |
|---|---|
| Lowest since issue | 0.5 € |
| Spread | 0.01 € |
| Spread % | 0.60% |
Company Profile
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Sector
-
Consensus: Galapagos NV
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
26.9
EUR
Average target price
37.03
EUR
Spread / Average Target
+37.66%
- Stock Market
- Certificates
- VQ8LB Certificat